{"filing":{"accession_number":"0001193125-26-274135","cik":"0001484612","ticker":"OM","company_name":"Outset Medical, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"om-20260614.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1484612/000119312526274135/om-20260614.htm"},"events":[{"id":11526,"run_id":10122,"accession_number":"0001193125-26-274135","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028, representing a significant multi-year commercial commitment affecting the company's revenue pipeline.","company_name":"Outset Medical, Inc.","ticker":"OM","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8130,"accession_number":"0001193125-26-274135","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028. While this is technically a contract amendment rather than a traditional M\u0026A transaction, it represents a material commercial commitment that would affect investor assessment of the company's revenue pipeline and customer relationships. The $40 million aggregate contract value and multi-year commitment structure qualify this as material under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:11.595698+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8130,"accession_number":"0001193125-26-274135","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028. While this is technically a contract amendment rather than a traditional M\u0026A transaction, it represents a material commercial commitment that would affect investor assessment of the company's revenue pipeline and customer relationships. The $40 million aggregate contract value and multi-year commitment structure qualify this as material under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:11.595698+00:00","company_name":"Outset Medical, Inc.","ticker":"OM","filing_date":"2026-06-17"},{"id":8131,"accession_number":"0001193125-26-274135","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.65,"reasoning":"The disclosure reiterates previously issued 2026 guidance and defers detailed financial impact disclosure to later in the year pending visibility on implementation timing. This is a guidance reiteration rather than an earnings release (no actual results disclosed), and the Item 2.02 safe-harbor language explicitly disclaims filing status. While the reference to an \"Amendment\" suggests a material transaction occurred elsewhere in the filing, this particular section contains only forward-looking guidance statements without concrete financial results or material event details.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:11.595698+00:00","company_name":"Outset Medical, Inc.","ticker":"OM","filing_date":"2026-06-17"}]}